245 related articles for article (PubMed ID: 32798741)
1. Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy.
Liu Q; Wang C; Zheng Y; Zhao Y; Wang Y; Hao J; Zhao X; Yi K; Shi L; Kang C; Liu Y
Biomaterials; 2020 Nov; 258():120275. PubMed ID: 32798741
[TBL] [Abstract][Full Text] [Related]
2. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
5. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
6. Optimisation of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 : single-guide RNA (sgRNA) delivery system in a goat model.
Huang Y; Ding Y; Liu Y; Zhou S; Ding Q; Yan H; Ma B; Zhao X; Wang X; Chen Y
Reprod Fertil Dev; 2019 Aug; 31(9):1533-1537. PubMed ID: 31079595
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
8. Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy.
Zhang Z; Wang Q; Liu Q; Zheng Y; Zheng C; Yi K; Zhao Y; Gu Y; Wang Y; Wang C; Zhao X; Shi L; Kang C; Liu Y
Adv Mater; 2019 Dec; 31(51):e1905751. PubMed ID: 31709671
[TBL] [Abstract][Full Text] [Related]
9. PLGA-Nanoparticles for Intracellular Delivery of the CRISPR-Complex to Elevate Fetal Globin Expression in Erythroid Cells.
Cruz LJ; van Dijk T; Vepris O; Li TMWY; Schomann T; Baldazzi F; Kurita R; Nakamura Y; Grosveld F; Philipsen S; Eich C
Biomaterials; 2021 Jan; 268():120580. PubMed ID: 33321292
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
11. Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier.
Wang P; Zhang L; Xie Y; Wang N; Tang R; Zheng W; Jiang X
Adv Sci (Weinh); 2017 Nov; 4(11):1700175. PubMed ID: 29201613
[TBL] [Abstract][Full Text] [Related]
12. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
13. A Genome-Editing Nanomachine Constructed with a Clustered Regularly Interspaced Short Palindromic Repeats System and Activated by Near-Infrared Illumination.
Peng H; Le C; Wu J; Li XF; Zhang H; Le XC
ACS Nano; 2020 Mar; 14(3):2817-2826. PubMed ID: 32048826
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
[TBL] [Abstract][Full Text] [Related]
15. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
16. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
Zhang X; Cheng C; Sun W; Wang H
Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
[TBL] [Abstract][Full Text] [Related]
17. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
18. CRISPR technology for immuno-oncology applications.
Wang J; Balan V; Marincola F
Methods Enzymol; 2020; 635():251-266. PubMed ID: 32122549
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (
Shen Y; Cohen JL; Nicoloro SM; Kelly M; Yenilmez B; Henriques F; Tsagkaraki E; Edwards YJK; Hu X; Friedline RH; Kim JK; Czech MP
J Biol Chem; 2018 Nov; 293(44):17291-17305. PubMed ID: 30190322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
